-
2023-509566-38-00
9
2024-08-05
gastroesophageal junction adenocarcinoma
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2023-503523-25-00
4
2024-02-29
Non-small cell lung cancer
-
2022-502660-20-00
5
2024-01-23
Follicular lymphoma
-
2023-504247-13-00
4
2023-10-17
Large cell neuroendocrine carcinoma
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-512119-34-00
4
2022-06-20
MSI-H/dMMR metastatic colorectal cancer
-
2023-505261-84-00
5
2020-10-06
Primary high risk leiomyosarcoma or liposarcoma of retroperitoneal spa
-
2024-520238-31-01
9
2026-04-20
Advanced Lung Cancer
-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2024-518167-35-01
4
2025-12-19
Patients with Metastatic Osteosarcoma
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-519261-21-00
4
2025-11-21
Desmoplastic small round cell tumor
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-515215-21-00
6
2025-10-24
DESMOID TUMOURS/AGGRESSIVE FIBROMATOSIS (DT/AF)
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-514947-27-00
9
2025-06-18
Advance solid tumors
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2023-506539-14-00
3
2025-05-27
Oncology